Vera Therapeutics Vera logo

News Releases

March 28, 2023

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeks 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on track for the second … Read more
February 27, 2023

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team … Read more
February 6, 2023

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its … Read more
February 1, 2023

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its … Read more
February 1, 2023

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering, … Read more
January 30, 2023

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending … Read more
January 25, 2023

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

BRISBANE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that it will host a virtual key opinion … Read more
January 3, 2023

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients … Read more
Top